Volume 13 Issue 4
Jul.  2022
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2022  >  13(4): 495-502
He Yue, Zheng Jin, Li Yang, et al. Efficacy and safety of basiliximab and antithymocyte globulin in immune induction in kidney transplantation: a Meta-analysis[J]. ORGAN TRANSPLANTATION, 2022, 13(4): 495-502. doi: 10.3969/j.issn.1674-7445.2022.04.013
Citation: He Yue, Zheng Jin, Li Yang, et al. Efficacy and safety of basiliximab and antithymocyte globulin in immune induction in kidney transplantation: a Meta-analysis[J]. ORGAN TRANSPLANTATION, 2022, 13(4): 495-502. doi: 10.3969/j.issn.1674-7445.2022.04.013
shu

Efficacy and safety of basiliximab and antithymocyte globulin in immune induction in kidney transplantation: a Meta-analysis

doi: 10.3969/j.issn.1674-7445.2022.04.013

  • Department of Urology, Suining Central Hospital, Suining 629000, China

More Information
  • Corresponding author: Feng Yougang, Email: uroygfeng@sina.com
  • Received Date: 2022-03-20
    Available Online: 2022-07-14
  • Publish Date: 2022-07-15
    Abstract
  •   Objective  To evaluate the efficacy and safety of basiliximab (BAS) and antithymocyte globulin (ATG) in immune induction therapy in kidney transplantation by systematic review and Meta-analysis.  Methods  Prospective randomized controlled clinical trials screening and comparing BAS and ATG in immune induction therapy in kidney transplantation were systematically searched from global databases, screened and compared. The quality of clinical trials was evaluated by Jadad scoring system and data extraction was performed. The effects of BAS and ATG on the incidence of acute rejection, survival rate of kidney allografts, survival rate of recipients, incidence of delayed graft function, infection, cytomegalovirus infection, malignant tumor, leukopenia and thrombocytopenia at 1 year after kidney transplantation were analyzed.  Results  A total of 10 clinical trials in English consisting of 1 721 kidney transplant recipients were searched, including 883 cases in the ATG group and 838 cases in the BAS group. No significant differences were observed in the incidence of acute rejection, survival rate of kidney allografts, survival rate of recipients, incidence of delayed graft function, infection, cytomegalovirus infection and thrombocytopenia at postoperative 1 year between the ATG and BAS groups (all P > 0.05). The incidence of malignant tumor and leukopenia at postoperative 1 year in the ATG group were significantly higher than those in the BAS group (both P < 0.05).  Conclusions  The use of ATG and BAS for immune induction therapy in kidney transplantation yield equivalent efficacy at postoperative 1 year, but BAS is safer than ATG. Clinical trials related to stratified analyses of immune risk are urgently required to achieve individualized precision treatment.

     

    • FullText(HTML)
  • loading
    • References(30)
  • [1]
    GOLSHAYAN D, PASCUAL M. Burden of end-stage renal disease and evolving challenges in kidney transplantation[J]. Transpl Int, 2019, 32(9): 889-891. DOI: 10.1111/tri.13490.
    [2]
    潘佳善, 苏涌, 朱道方, 等. 公民逝世捐献与活体捐献肾移植的近期临床效果[J]. 实用医学杂志, 2022, 38(2): 184-189. DOI: 10.3969/j.issn.1006-5725.2022.02.011.

    PAN JS, SU Y, ZHU DF, et al. Clinical effects of deceased vs living donor on kidney transplantation[J]. J Pract Med, 2022, 38(2): 184-189. DOI: 10.3969/j.issn.1006-5725.2022.02.011.
    [3]
    COOPER JE. Evaluation and treatment of acute rejection in kidney allografts[J]. Clin J Am Soc Nephrol, 2020, 15(3): 430-438. DOI: 10.2215/CJN.11991019.
    [4]
    RODRIGO E, CHEDID MF, SEGUNDO DS, et al. Acute rejection following kidney transplantation: state-of-the-art and future perspectives[J]. Curr Pharm Des, 2020, 26(28): 3468-3496. DOI: 10.2174/1381612826666200610184433.
    [5]
    BAUER AC, FRANCO RF, MANFRO RC. Immunosuppression in kidney transplantation: state of the art and current protocols[J]. Curr Pharm Des, 2020, 26(28): 3440-3450. DOI: 10.2174/1381612826666200521142448.
    [6]
    POSNER J, BARRINGTON P, BRIER T, et al. Monoclonal antibodies: past, present and future[J]. Handb Exp Pharmacol, 2019, 260: 81-141. DOI: 10.1007/164_2019_323.
    [7]
    司霞, 孙楚枫, 陈月, 等. 康柏西普辅助玻璃体切割术治疗增生性糖尿病视网膜病变的Meta分析[J]. 中华实验眼科杂志, 2020, 38(9): 773-780. DOI: 10.3760/cma.j.cn115989-20200715-00498.

    SI X, SUN CF, CHEN Y, et al. A Meta-analysis of the effects of intravitreal conbercept as an adjunct before vitrectomy in proliferative diabetic retinopathy[J]. Chin J Exp Ophthalmol, 2020, 38(9): 773-780. DOI: 10.3760/cma.j.cn115989-20200715-00498.
    [8]
    MAIER HT, ASHRAF MI, DENECKE C, et al. Prediction of delayed graft function and long-term graft survival by serum and urinary neutrophil gelatinase-associated lipocalin during the early postoperative phase after kidney transplantation[J]. PLoS One, 2018, 13(1): e0189932. DOI: 10.1371/journal.pone.0189932.
    [9]
    SOLLINGER H, KAPLAN B, PESCOVITZ MD, et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection[J]. Transplantation, 2001, 72(12): 1915-1919. DOI: 10.1097/00007890-200112270-00008.
    [10]
    LEBRANCHU Y, BRIDOUX F, BÜCHLER M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy[J]. Am J Transplant, 2002, 2(1): 48-56. DOI: 10.1034/j.1600-6143.2002.020109.x.
    [11]
    TULLIUS SG, PRATSCHKE J, STROBELT V, et al. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results[J]. Transplant Proc, 2003, 35(6): 2100-2101. DOI: 10.1016/s0041-1345(03)00679-1.
    [12]
    MOURAD G, ROSTAING L, LEGENDRE C, et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids[J]. Transplantation, 2004, 78(4): 584-590. DOI: 10.1097/01.tp.0000129812.68794.cc.
    [13]
    BRENNAN DC, DALLER JA, LAKE KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation[J]. N Engl J Med, 2006, 355(19): 1967-1977. DOI: 10.1056/NEJMoa060068.
    [14]
    KYLLÖNEN LE, EKLUND BH, PESONEN EJ, et al. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety[J]. Transplantation, 2007, 84(1): 75-82. DOI: 10.1097/01.tp.0000268084.64888.f3.
    [15]
    PILCH NA, TABER DJ, MOUSSA O, et al. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation[J]. Ann Surg, 2014, 259(5): 888-893. DOI: 10.1097/SLA.0000000000000496.
    [16]
    PATEL HV, KUTE VB, VANIKAR AV, et al. Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation[J]. Saudi J Kidney Dis Transpl, 2014, 25(4): 819-822. DOI: 10.4103/1319-2442.135057.
    [17]
    TEDESCO-SILVA H, FELIPE C, FERREIRA A, et al. Reduced Incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses[J]. Am J Transplant, 2015, 15(10): 2655-2664. DOI: 10.1111/ajt.13327.
    [18]
    THOMUSCH O, WIESENER M, OPGENOORTH M, et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial[J]. Lancet, 2016, 388(10063): 3006-3016. DOI: 10.1016/S0140-6736(16)32187-0.
    [19]
    LIM WH, JOHNSON DW, TEIXEIRA-PINTO A, et al. Association between duration of delayed graft function, acute rejection, and allograft outcome after deceased donor kidney transplantation[J]. Transplantation, 2019, 103(2): 412-419. DOI: 10.1097/TP.0000000000002275.
    [20]
    陈莉萍, 莫春柏, 田军, 等. ATG-F单次大剂量与多次低剂量给药应用于肾移植诱导治疗的有效性和安全性[J]. 中华器官移植杂志, 2017, 38(11): 665-670. DOI: 10.3760/cma.j.issn.0254-1785.2017.11.006.

    CHEN LP, MO CB, TIAN J, et al. Efficacy and safety of single high-dose versus multiple low-dose ATG-Fresenius induction in de novo renal transplantation[J]. Chin J Organ Transplant, 2017, 38(11): 665-670. DOI: 10.3760/cma.j.issn.0254-1785.2017.11.006.
    [21]
    朱焓, 徐鸿, 梁国标. 个体化免疫诱导方案在肾移植中的应用进展[J]. 器官移植, 2021, 12(6): 741-747. DOI: 10.3969/j.issn.1674-7445.2021.06.015.

    ZHU H, XU H, LIANG GB. Application progress of individualized immune induction therapy in kidney transplantation[J]. Organ Transplant, 2021, 12(6): 741-747. DOI: 10.3969/j.issn.1674-7445.2021.06.015.
    [22]
    CHOI J, CHANDRAKER A. Immunologic risk assessment and approach to immunosuppression regimen in kidney transplantation[J]. Clin Lab Med, 2019, 39(4): 643-656. DOI: 10.1016/j.cll.2019.07.010.
    [23]
    HART A, SMITH JM, SKEANS MA, et al. OPTN/SRTR 2015 annual data report: kidney[J]. Am J Transplant, 2017, 17(Suppl 1): 21-116. DOI: 10.1111/ajt.14124.
    [24]
    关兆杰, 刘杰, 钱雷, 等. 肾移植免疫诱导方案的比较研究[J]. 中华器官移植杂志, 2019, 40(7): 419-422. DOI: 10.3760/cma.j.issn.0254-1785.2019.07.009.

    GUAN ZJ, LIU J, QIAN L, et al. Comparative study of induction therapy during kidney transplantation[J]. Chin J Organ Transplant, 2019, 40(7): 419-422. DOI: 10.3760/cma.j.issn.0254-1785.2019.07.009.
    [25]
    JEONG R, QUINN RR, LENTINE KL, et al. Incidence, risk factors, and outcomes of kidney transplant recipients treated with both basiliximab and antithymocyte globulin. [J] Can J Kidney Health Dis, 2020, 7: 2054358120964061. DOI: 10.1177/2054358120964061.
    [26]
    AZZOPARDI N, LONGUET H, TERNANT D, et al. Relationship between antithymocyte globulin concentrations and lymphocyte sub-populations in kidney transplant patients[J]. Clin Pharmacokinet, 2022, 61(1): 111-122. DOI: 10.1007/s40262-021-01053-7.
    [27]
    MEHTA RB, SHIMKO K, ZHANG X, et al. Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation[J]. Clin Transplant, 2022, 36(4): e14582. DOI: 10.1111/ctr.14582.
    [28]
    董塬, 邵笑笑, 周华. 个体化免疫诱导方案在公民逝世后捐献肾移植患者中的疗效观察[J]. 中国药物与临床, 2020, 20(20): 3402-3404. DOI: 10.11655/zgywylc2020.20.019.

    DONG Y, SHAO XX, ZHOU H. Efficacy of individualized immunoinduction program in patients after kidney transplantation from organ donation after citizen's death[J]. Chin Remed Clin, 2020, 20(20): 3402-3404. DOI: 10.11655/zgywylc2020.20.019.
    [29]
    LENTINE KL, SCHNITZLER MA, XIAO H, et al. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 study participants[J]. Trials, 2015, 16: 365. DOI: 10.1186/s13063-015-0891-y.
    [30]
    EL TERS M, SMITH BH, COSIO FG, et al. Competing risk analysis in renal allograft survival: a new perspective to an old problem[J]. Transplantation, 2021, 105(3): 668-676. DOI: 10.1097/TP.0000000000003285.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (459) PDF downloads(105) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return